Hetero Drugs Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is PANTOPRAZOLE SODIUM SESQUIHYDRATE, with a corresponding US DMF Number 20271.
Remarkably, this DMF maintains an Active status since its submission on February 13, 2007, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 27, 2013, and payment made on February 01, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II